← All trials
NCT05268172
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2022
- Primary completion
- Dec 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- Mar 7, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangnan UniversityLead sponsor
- Central South UniversityCollaborator
- Sichuan UniversityCollaborator
- Sichuan UniversityCollaborator
- Zhejiang UniversityCollaborator
- Jiangnan UniversityOverall official - principal investigator
- Jiangnan UniversityStudy director
- Wuxi People's HospitalCollaborator
- China Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.